Prescribing Trends and Health Care Expenditure of P2Y12 Prescriptions in Australia Over the Last Decade

Nowbar, 2019, Mortality From Ischemic Heart Disease, Circ Cardiovasc Qual Outcomes, 12, 10.1161/CIRCOUTCOMES.118.005375 Mortality, 2016, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet, 388, 1459, 10.1016/S0140-6736(16)31012-1 Australian Bureau of Statistics. Causes of Death 2017 2018. ABS cat. no. 3303.0. Available from: https://www.abs.gov.au/ausstats/[email protected]/Lookup/by%20Subject/3303.0∼2017∼Main%20Features∼Australia's%20leading%20causes%20of%20death,%202017∼2 Australian Institute of Health and Welfare. Cardiovascular disease: Australian facts 2011. Cat. no. CVD 53 ed. Canberra: AIHW2011. Available from: https://www.aihw.gov.au/reports/heart-stroke-vascular-disease/cardiovascular-disease-australian-facts-2011/summary Levine, 2016, 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 68, 1082, 10.1016/j.jacc.2016.03.513 Gan, 2015, Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis, Curr Med Res Opin, 31, 2313, 10.1185/03007995.2015.1098600 Pol, 2019, NOACs Now Mainstream for the Use of Anticoagulation in Non-Valvular Atrial Fibrillation in Australia, Heart Lung Circ, 28, e40, 10.1016/j.hlc.2018.03.010 Norgard, 2009, Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention, Vasc Health Risk Manag, 5, 873, 10.2147/VHRM.S5699 Guan, 2018, Keping Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention, Medicine, 97, 10.1097/MD.0000000000012978 Medical Benefits Scheme. Medicare statistics for Item No. 38306 between 2010 to 2019 2020. Available from: http://medicarestatistics.humanservices.gov.au/statistics/do.jsp?_PROGRAM=%2Fstatistics%2Fmbs_item_standard_report&DRILL=ag&group=38306&VAR=services&STAT=count&RPT_FMT=by+time+period+and+state&PTYPE=calyear&START_DT=201001&END_DT=201912. Accessed November 7, 2021. Wallentin, 2009, Ticagrelor versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 361, 1045, 10.1056/NEJMoa0904327 Wiviott, 2007, Prasugrel versus clopidogrel in patients with acute coronary syndromes, N Engl J Med, 357, 2001, 10.1056/NEJMoa0706482 Saunders C. Economic Cost of Acute Coronary Syndrome in Australia: The Cost to Governments. Internet Heart Foundation; 2017. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa0706482. Bonaca, 2016, Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial, JAMA Cardiol, 1, 425, 10.1001/jamacardio.2016.1017 Turgeon, 2020, Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention, JAMA Internal Medicine, 180, 420, 10.1001/jamainternmed.2019.6447 You, 2020, Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention, JAMA, 324, 1640, 10.1001/jama.2020.16167 Schupke, 2019, Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes, N Engl J Med, 381, 1524, 10.1056/NEJMoa1908973 Collet, 2020, European Heart Journal, 42, 1289, 10.1093/eurheartj/ehaa575 Coughlan, 2021, Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial, JAMA Cardiology, 6, 1121, 10.1001/jamacardio.2021.2228 Australian Therapeutic Goods Administration. Prescription medicines: registration of new generic medicines and biosimilar medicines. Australian Therapeutic Goods Administration 2020. Available from: https://www.tga.gov.au/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines. Accessed November 7, 2021. Khalid, 2019, Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry), Am J Cardiol, 124, 1807, 10.1016/j.amjcard.2019.09.003 Jain, 2019, Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis, Cardiovasc Drugs Ther, 33, 511, 10.1007/s10557-019-06913-w Sheikh Rezaei, 2017, Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014, Int J Cardiol, 235, 61, 10.1016/j.ijcard.2017.02.096